

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re CONTINUATION APPLICATION of:)
)
THOMAS et al.) Group Art Unit: 1624
)
Parent Appln. No.: 10/080,716) Examiner: Patel, S.
)
Parent Appln. Filed: February 25, 2002)
)
FOR: QUINAZOLINE DERIVATIVES AND)
PHARMACEUTICAL COMPOSITIONS)
CONTAINING THEM)

Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, **Mail Stop Patent Application**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Date: November 3, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed concurrently with the filing of this Continuation Application of copending Application No. 10/080,716.

Copies of the listed documents were previously submitted or cited by the Examiner in parent Application No. 10/080,716. Accordingly, no copies of the listed documents are provided herewith. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." If the Examiner applies the documents as "prior art" against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

EXCEPT for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: November 3, 2003
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 To: U.S. Department of Commerce Patent and Trademark Office		Atty. Dkt. No.	M#	Client Ref.
			056291-5005-02	Z.70188/UST
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: THOMAS et al.		
		Appln. No.: Continuation of 10/080,716		
		Filing Date: November 3, 2003		
		Prior Examiner: S. Patel	Prior Group Art Unit: 1624	
Date: November 3, 2003		Page 1 of 8		

U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	3,266,990	Aug-66	Lutz et al.		
	BR	4,343,940	Aug-82	Kreighbaum et al.		
	CR	5,373,011	Dec-94	Haley		
	DR	5,409,930	Apr-95	Spada et al.		
	ER	5,411,963	May-95	Dreikorn et al.		
	FR	5,480,883	Jan-96	Spada et al.		
	GR	5,571,815	Nov. 96	Schaper et al.		
	HR	5,646,153	Jul-97	Spada et al.		
	IR	5,650,415	Jul-97	Tang et al.		
	JR	5,656,643	Aug-97	Spada et al.		
	KR	5,710,158	Jan-98	Myers et al.		
	LR	5,712,395	Jan-98	App et al.		
	MR	5,714,493	Feb-98	Myers et al.		
	NR	5,721,237	Feb-98	Myers et al.		

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
	OR	0 326 307 A2	Feb-89	EPA	Nomoto et al.				
	PR	0 326 330 A2	Aug-89	EPA	Arnold et al.				
	QR	0 520 722 A1	Dec-92	EPA	Barker et al.				
	RR	0 602 851 A1	Jun-94	EPA	Barker et al.				
	SR	0 635 498 A1	Jan-95	EPA	Barker				
	TR	0 635 507 A1	Jan-95	EPA	Barker				
	UR	0 743 308	Nov-96	EPA	Jinbo et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)								
YR	Arya et al., Nitroimidazoles: Part XVI - Some 1-Methyl-4-nitro-5-substituted Imidazoles, Indian Journal of Chemistry, Vol. 21B, Dec. 1982, pp. 1115-1117							
ZR	Bridges, "The current status of tyrosine kinase inhibitors ...," Exp.Opin.Ther.Patents (1995), 5(12): 1245-1257, Editorial, Oncologic, Endocrine & Metabolic, 1995 Ashley Publications Ltd ISSN 1354-3776.							
AAR	Bridges, et al., "Enantioselective Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by 4-(a-Phenethylamino)quinazolines," Bioorganic & Medicinal Chemistry, Vol. 3, No. 12, pp. 1651-1656, 1995.							

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 To: U.S. Department of Commerce Patent and Trademark Office	Atty. Dkt. No.	M#	Client Ref.
		056291-5005-02	Z.70188/UST
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant: THOMAS et al.		
	Appln. No.: Continuation of 10/080,716		
	Filing Date: November 3, 2003		
Date: November 3, 2003	Page 2 of 8	Prior Examiner: S. Patel	Prior Group Art Unit: 1624

U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	5,736,534	Arnold			
	BR	5,747,498	Schnur et al.			
	CR	5,792,771	App et al.			
	DR	5,929,080	Frost			
	ER	6,002,008	Wissner et al.			
	FR	6,057,320	Spada et al.			
	GR	Re. 36,265	Spada et al.			
	HR	5,952,333	Barker			
	IR	5,955,464	Barker			
	JR	5,962,458	Lohmann et al.			
	KR	6,015,814	Barker			
	LR	6,071,921	Lohmann et al.			
	MR	6,184,225	Thomas et al.			

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
	NR	0 787 722 A1	Aug-97	EPA	Wissner et al.				
	OR	0 837 063 A1	Apr-98	EPA	Arnold et al.				
	PR	2 033 894 A	May-80	GB	Kobayashi et al.				
	QR	0 566 226 A1	10/1993	EP	Barker et al.				
	RR	97/32856	09/1997	WIPO	Thomas et al.				
	SR	2 160 201 A	Dec-85	GB	Boyle et al.				
	TR	DE 02213558	Oct-72	Germany	Hughes et al.				
	UR	DE 19614718	Oct-97	Germany	Braun et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)							
	VR	Connolly, et al., "Human Vascular Permeability Factor," J.Bio.Chem., Vol. 264, No. 33, November 1989, pp. 20017-20024.					
	WR	Cullinan-Bove, et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor Expression in the Rat Uterus...", Endocrinology, Vol. 133, No. 2, 1993, pp. 829-837.					
	XR	Fan, et al., "Controlling the Vasculature: Angiogenesis, Anti-Angiogenesis...", TIPS Review, Vol. 16, February 1995, pp. 57-65.					
	YR	Folkman, "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease," Nature Medicine, Vol. 1, No. 1, 1995, pp. 27-30.					

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 To: U.S. Department of Commerce Patent and Trademark Office		Atty. Dkt. No.	M#	Client Ref.
			056291-5005-02	Z.70188/UST
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: THOMAS et al.		
		Appln. No.: Continuation of 10/080,716		
		Filing Date: November 3, 2003		
Date: November 3, 2003		Page 3 of 8		Prior Examiner: S. Patel
Prior Group Art Unit: 1624				

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	5,457,105	Barker			
	BR	5,475,001	Barker			
	CR	5,569,658	Barker			
	DR	5,580,870	Barker et al.			
	ER	5,616,582	Barker			
	FR	5,770,599	Gibson			
	GR	5,770,603	Gibson			
	HR	5,814,630	Barker et al.			
	IR	5,821,246	Brown et al.			
	JR	5,866,572	Barker et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
				Enclosed	No	Enclose	No
KR	54-2327	Sep-79	Japan				
LR	WO 87/04321	Jul-87	WIPO	Manning et al.			
MR	WO 92/14716	Sep-92	WIPO	Coe et al.			
NR	WO 92/16527	Oct-92	WIPO	Kasahara et al.			
OR	WO 92/20642	Nov-92	WIPO	Spada et al.			
PR	WO 95/15758	Jun-95	WIPO	Myers et al.			
QR	WO 95/19169	Jul-95	WIPO	Hirth et al.			

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

RR	Fry et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," SCIENCE, Vol 265, 08/19/94, pp. 1093-95.			
SR	Gazit et al., Tyrophostins IV-Highly Potent Inhibitors...Relationship Study of 4-Anilidoquinazolines, Bioorganic & Medicinal Chemistry, Vol. 4, No. 8, 1996, pp. 1203-1207			
TR	Golovkin et al., Nauchin TR-VSES-NAUCHNO-ISSLED INST FARM, 1990, 28, 70-75			
UR	Klohs et al., "Antiangiogenic Agents", Curr. Opin. Biotech, 1/6, 1999, 544-549 (Abstract Attached)			
VR	Higashino et al., "Reactions of the Anion of Quinazoline Reissert Compound (3-Benzoyl-3,4-dihydro-4-quinazolinecarbonitrile) with Electrophiles", Chem. Phar. Bull. 33(3), 1985, pp. 950-961			
WR				

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 To: U.S. Department of Commerce Patent and Trademark Office				Atty. Dkt. No.	M#	Client Ref.				
				056291-5005-02		Z.70188/UST				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: THOMAS et al.						
				Appln. No.: Continuation of 10/080,716						
				Filing Date: November 3, 2003						
				Prior Examiner: S. Patel		Prior Group Art Unit: 1624				
Date: November 3, 2003 Page 4 of 8										
U.S. PATENT DOCUMENTS										
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)			
	AR	5,932,574	08/1999	Barker						
	BR	5,942,514	08/1999	Barker						
	CR									
	DR									
	ER									
FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available		
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
	FR	WO 95/21613	Aug-95	WIPO	Gazit et al.					
	GR	WO 95/23141	Aug-95	WIPO	Arnold					
	HR	WO 95/24190	Sep-95	WIPO	Chen et al.					
	IR	WO 96/09294	Mar-96	WIPO	Hudson et al.					
	JR	WO 96/15118	May-96	WIPO	Brown et al.					
	KR	WO 96/16960	Jun-96	WIPO	Barker					
	LR	WO 96/29331 Abs	Sep-96	WIPO	Himmelsbach et al.					
	MR	WO 96/30347	Oct-96	WIPO	Schnur et al.					
	NR	WO 96/30370	Oct-96	WIPO	Matsuo et al.					
	OR	WO 96/33977	Oct-96	WIPO	Barker					
	PR	WO 96/33978	Oct-96	WIPO	Barker					
	QR	WO 96/33979	Oct-96	WIPO	Barker					
	RR	WO 96/33980	Oct-96	WIPO	Gibson					
	SR	WO 96/33981	Oct-96	WIPO	Barker					
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)										
	TR	Hara et al., On the Amination of Azaheterocycles. A New Procedure for the Introduction of an Amino Group (1), J. Heterocyclic Chem. Vol. 19, 1982, pp. 1285-1287								
	UR	Iyer, et al., "Studies in Potential Amoebicides: Part III-Synthesis of 4-Substituted Amino-8-Hydroxy) Quinazolines & 3-Substituted 8-Hydroxy(&8-Methoxy)-4-Quinazolones," J.Sci.Industr.Res., Vol. 15C, January 1956, pp.1-7.								
	VR	Jakeman, et al., "Developmental Expression of Binding Sites and Messenger Ribonucleic Acid...", Endocrinology, Vol. 133, No. 2, 1993, pp. 848-859.								
	WR									
Examiner						Date Considered:				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.										

FORM PTO-1449 To: U.S. Department of Commerce Patent and Trademark Office					Atty. Dkt. No.	M#	Client Ref.			
					056291-5005-02		Z.70188/UST			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Applicant: THOMAS et al.					
					Appln. No.: Continuation of 10/080,716					
					Filing Date: November 3, 2003					
Date: November 3, 2003 Page 5 of 8					Prior Examiner: S. Patel		Prior Group Art Unit: 1624			
U.S. PATENT DOCUMENTS										
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)		Class	Sub Class	Filing Date (if appropriate)		
	AR									
	BR									
	CR									
	DR									
	ER									
FOREIGN PATENT DOCUMENTS										
		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
							Enclosed	No	Enclose	No
	FR	WO 96/39145	Dec-96	WIPO	Myers et al.					
	GR	WO 96/40648	Dec-96	WIPO	Tang et al.					
	HR	WO 96/40673	Dec-96	WIPO	Tang et al.					
	IR	WO 97/02266	Jan-97	WIPO	Traxler et al.					
	JR	WO 97/03069	Jan-97	WIPO	Cockerill et al.					
	KR	WO 97/17329	May-97	WIPO	Kubo et al.					
	LR	WO 97/28161	Aug-97	WIPO	Altmann et al.					
	MR	WO 97/30034	Aug-97	WIPO	Barker et al.					
	NR	WO 97/30035	Aug-97	WIPO	Thomas et al.					
	OR	WO 97/30044	Aug-97	WIPO	Barker et al.					
	PR	WO 97/34876	Sep-97	WIPO	Thomas et al.					
	QR	WO 97/37999	Oct-97	WIPO	Gold					
	RR	WO 97/38983	Oct-97	WIPO	Bridges et al.					
	SR	WO 97/38994	Oct-97	WIPO	Gibson					
	TR	WO 97/42187	Nov-97	WIPO	Thomas et al.					
	UR	WO 97/49689	Dec-97	WIPO	Brasca et al.					
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)										
	VR	Karminski et al., The Synthesis of Some Quinazoline Derivatives and Their Biological Properties; J. Environ. Sci. Health, Vol B18, 1983, pp. 599-610								
	WR	Kim, et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in Vivo," Nature, Vol. 362, April 1993, pp. 841-844.								
	XR	Kobayashi, Derwent Abstract 82-87077, Vol. 6, No. 244, 12/1982, JP 57-144266, 09/1982, "4-Anilinoquinazoline Derivative, its Preparation and Analgesic and Antiphlogistic Agent Containing Said Derivative as Active Component". (n.7)								
Examiner						Date Considered:				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.										

FORM PTO-1449 To: U.S. Department of Commerce Patent and Trademark Office				Atty. Dkt. No.	M#	Client Ref.		
					056291-5005-02	Z.70188/UST		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: THOMAS et al.				
				Appln. No.: Continuation of 10/080,716				
				Filing Date: November 3, 2003				
				Prior Examiner: S. Patel		Prior Group Art Unit: 1624		
Date: November 3, 2003 Page 6 of 8								
U.S. PATENT DOCUMENTS								
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)		Class	Sub Class	Filing Date (if appropriate)
	AR							
	BR							
	CR							
	DR							
	ER							
FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No
	FR	WO 98/02434	Jan-98	WIPO	Cockerill et al.			
	GR	WO 98/10767	Mar-98	WIPO	McMahon et al.			
	HR	WO 98/13350	Apr-98	WIPO	Thomas et al.			
	IR	WO 98/14431	Apr-98	WIPO	Matsuno et al.			
	JR	WO 98/23613	Jun-98	WIPO	Arnold et al.			
	KR	WO 98/35958	Aug-98	WIPO	Bold et al.			
	LR	WO 98/43960	Oct-98	WIPO	Wissner et al.			
	MR	WO 98/50038	Nov-98	WIPO	Frost			
	NR	WO 99/06378	Feb-99	WIPO	Bridges			
	OR	WO 99/06396	Feb-99	WIPO	Bridges			
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)								
	PR	Kolch, et al., "Regulation of the Expression of the VEGF/VPS and its Receptors: Role in Tumor Angiogenesis," Breast Cancer Research and Treatment, Vol. 36, 1995, pp. 139-155.						
	QR	Kumar et al., Reactions of Diazines with Nucleophiles-IV.1 The Reactivity...Single Electron Transfer Reactions, Bioorganic & Medicinal Chemistry, Vol. 3, No. 7, 1995, pp. 891-897						
	RR	Kyorin, Derwent Abstract 84-53835, JP 59-13765, 01/1984, "2-(4-Quinazoliny)amino benzoic acid derivs....having analgesic and antiinflammatory activities". (n.8)						
	SR							
Examiner					Date Considered:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.								

FORM PTO-1449 To: U.S. Department of Commerce Patent and Trademark Office				Atty. Dkt. No.	M#	Client Ref.		
				056291-5005-02		Z.70188/UST		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: THOMAS et al.				
				Appln. No.: Continuation of 10/080,716				
				Filing Date: November 3, 2003				
Date: November 3, 2003		Page 7 of 8		Prior Examiner: S. Patel		Prior Group Art Unit: 1624		
U.S. PATENT DOCUMENTS								
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)		Class	Sub Class	Filing Date (if appropriate)
	AR							
	BR							
	CR							
	DR							
	ER							
FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No
	FR	WO 99/09016	Feb-99	WIPO	Wissner et al.			
	GR	WO 99/09024	Feb-99	WIPO	Chan et al.			
	HR	WO 99/10349	Mar-99	WIPO	Hennequin et al.			
	IR	WO 97/22596	Jun-97	PCI				
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)								
	JR	Li, et al., Chem.Abs., Vol. 92:76445u, 1980, p.674-675,						
	KR	Lin et al., Chem.Abs., Vol. 96:122728w, 1982, p.695,						
	LR	Nagarajan et al., Nitroimidazoles: Part XIX†-Structure Activity Relationships‡, Indian Journal of Chemistry, Vol. 23B, April 1984, pp. 342-362						
	MR	Nomoto et al., Studies on Cardiotonic Agents. VII.1) Potent Cardiotonic Agent KF15232 with Myofibrillar CA2+ Sensitizing Effect, Chem. Pharm. Bull., Vol. 39(4), 1991, pp. 900-910						
	NR	Rewcastle et al., "Tyrosine Kinase Inhibitors. 5 ... 4-(Phenylamino)quinazolines as Potent ... Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor," J.Med.Chem. 1995, Vol. 38, pp.3482-3487.						
	OR	Sankyo and Ube, Derwent Abstract 81-28290, JP 56-20577, 02/1981, "4-(N-alkyl:anilino) quinazoline derivs....having analgesic and antiinflammatory actions". (n.9)						
	PR	Schonowsky et al., Chinazolinderivate, ihre Herstellung und biologische Wirkung, Quinzaolines, their Preparation and Biological Activity, Z. Naturforsch, 37b, 1982, pp. 907-911						
Examiner					Date Considered:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.								

FORM PTO-1449 To: U.S. Department of Commerce Patent and Trademark Office				Atty. Dkt. No.	M#	Client Ref.	
					056291-5005-02	Z.70188/UST	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: THOMAS et al.			
				Appln. No.: Continuation of 10/080,716			
				Filing Date: November 3, 2003			
Date: November 3, 2003		Page 8 of 8		Prior Examiner: S. Patel		Prior Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)	
AR							
BR							
CR							
FOREIGN PATENT DOCUMENTS						English Abstract	
	Document Number	Date MM/YYYY	Country	Inventor Name		Translation Readily Available	
						Enclosed	No
DR							
ER							
FR							
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)							
GR	Senger, et al., "Vascular Permeability Factor (VPF, VEGF) in Tumor Biology," Cancer and Metastasis Reviews, Vol. 12, 1993, pp. 303-324.						
HR	Sinyak, et al., Synthesis and Biological Properties of Derivatives of 4-Heterylmercaptoquinazoline, Zaporozh'e Medical Institute pp. 103-106, translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 20, No. 2, Feb. 1986, 168-171, original article submitted 12/29/84						
IR	Spada, et al., "Small molecule inhibitors of tyrosine Kinase activity, Exp.Opin.Ther.Patents (1995), 5(8):805-817, Patent Update, Oncologic, Endocrine & Metabolic, Ashley Publications Ltd ISSN 1354-3776.						
JR	Stets et al., Investigation of Anti-Arrhythmic Action of Quinazopyrine, Pharmacology Dept., Zaporozhye Medical Institute, Zaporozhye, and Vinnitsa Medical Institute, Vinnitsa, pp. 94-96, translated from Farmakol. 1 toksik., Vol. 53, No. 3, 1990, pp. 15-17						
KR	Traxler, et al., "Recent advances in protein tyrosine kinase inhibitors," Drugs of the Future 1995, Vol. 20(12), pp. 1261-1274.						
LR	Vinogradoff et al., Development of a New Synthesis of...Sodium Salt via an Amidine Intermediate, J. Heterocyclic Chem. Vol. 26, 97, Jan.-Feb. 1989, pp. 97-103						
MR	Ward, et al., "Epidermal Growth Factor Receptor Tyrosine Kinase - Investigation of Catalytic Mechanism, Structure-Based Searching and Discovery of a Potent Inhibitor," Biochem.Pharmacology, Vol. 48, No. 4, pp. 659-666 (1994).						
NR	Wolfe et al., A Facile One-Step Synthesis of Certain 4-(4-Pyrimidinylmethyl)quinazolines, J. Heterocyclic Chem., Vol. 13, 1976, pp. 383-385						
OR							
PR							
Examiner				Date Considered:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							